menu
    • menu
    [{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Societal CDMO","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"InfectoPharm Drugs and Consilium \/ InfectoPharm Drugs and Consilium","highestDevelopmentStatusID":"15","companyTruncated":"InfectoPharm Drugs and Consilium \/ InfectoPharm Drugs and Consilium"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Societal CDMO","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"InfectoPharm Drugs and Consilium \/ Societal CDMO","highestDevelopmentStatusID":"15","companyTruncated":"InfectoPharm Drugs and Consilium \/ Societal CDMO"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"GKM Gesellschaft f\u00fcr Therapieforschung","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InfectoPharm Drugs and Consilium \/ GKM Gesellschaft f\u00fcr Therapieforschung","highestDevelopmentStatusID":"10","companyTruncated":"InfectoPharm Drugs and Consilium \/ GKM Gesellschaft f\u00fcr Therapieforschung"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"InfectoPharm Drugs and Consilium \/ InfectoPharm Drugs and Consilium","highestDevelopmentStatusID":"15","companyTruncated":"InfectoPharm Drugs and Consilium \/ InfectoPharm Drugs and Consilium"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Winicker Norimed GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InfectoPharm Drugs and Consilium \/ Winicker Norimed GmbH","highestDevelopmentStatusID":"10","companyTruncated":"InfectoPharm Drugs and Consilium \/ Winicker Norimed GmbH"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Winicker Norimed GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"InfectoPharm Drugs and Consilium \/ Winicker Norimed GmbH","highestDevelopmentStatusID":"10","companyTruncated":"InfectoPharm Drugs and Consilium \/ Winicker Norimed GmbH"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Gesellschaft f\u00fcr Therapieforschung mbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Sanacutan Basiscreme","moa":"Skin barrier","graph1":"Dermatology","graph2":"Phase III","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"InfectoPharm Drugs and Consilium \/ Gesellschaft f\u00fcr Therapieforschung mbH","highestDevelopmentStatusID":"10","companyTruncated":"InfectoPharm Drugs and Consilium \/ Gesellschaft f\u00fcr Therapieforschung mbH"}]

    Find Clinical Drug Pipeline Developments & Deals by InfectoPharm Drugs and Consilium

    Menu

    InfectoPharm Drugs and Consilium

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Permethrin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Winicker Norimed GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Therapy for Scabies With Two Differently Concentrated Permethrin Creams

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 23, 2024

                            Lead Product(s) : Permethrin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Winicker Norimed GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Recipient : Societal CDMO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Societal CDMO Signs Three-Year Manufacturing and Supply Agreement With InfectoPharm for Ritalin LA® in Europe

                            Details : Ritalin LA is indicated for the treatment of attention deficit hyperactivity disorder. The product is an extended-release formulation of methylphenidate hydrochloride with a bi-modal release profile using the proprietary SODAS® technology.

                            Product Name : Ritalin LA

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 05, 2022

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Recipient : Societal CDMO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Societal CDMO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Societal CDMO Signs Three-Year Manufacturing and Supply Agreement With InfectoPharm for Ritalin LA in Europe

                            Details : Ritalin LA is indicated for the treatment of attention deficit hyperactivity disorder. The product is an extended-release formulation of methylphenidate hydrochloride with a bi-modal release profile using the SODAS (Spheroidal Oral Drug Absorption System...

                            Product Name : Ritalin LA

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 05, 2022

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Societal CDMO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Recipient : Cosmo Pharmaceuticals

                            Deal Size : $4.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cosmo and Infectopharm Sign License for Winlevi® in Germany, Italy, and Austria

                            Details : Under the license agreement terms, Infectopharm will receive from Cosmo, the exclusive right to commercialize Winlevi (clascoterone) in Germany, Italy & Austria, which is indicated for acne vulgaris.

                            Product Name : Winlevi

                            Product Type : Other Small Molecule

                            Upfront Cash : $0.9 million

                            April 10, 2022

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Recipient : Cosmo Pharmaceuticals

                            Deal Size : $4.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : GKM Gesellschaft für Therapieforschung

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-E...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 29, 2021

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : GKM Gesellschaft für Therapieforschung

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Permethrin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Winicker Norimed GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)

                            Details : Undisclosed

                            Product Name : InfectoScab

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 24, 2021

                            Lead Product(s) : Permethrin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Winicker Norimed GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed

                            InfectoPharm Drugs and Consilium

                            Germany arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sanacutan Basiscreme

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Gesellschaft für Therapieforschung mbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 21, 2020

                            Lead Product(s) : Sanacutan Basiscreme

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Gesellschaft für Therapieforschung mbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth